Douglas S Goodin

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi request reprint Marijuana and multiple sclerosis
    Douglas Goodin
    Department of Neurology, University of California San Francisco, USA
    Lancet Neurol 3:79-80. 2004
  2. ncbi request reprint Treatment of multiple sclerosis with human beta interferon
    D S Goodin
    Department of Neurology, University of California at San Francisco, Fort Miley Veterans Administration Hospital, 94121, USA
    Int MS J 12:96-108. 2005
  3. ncbi request reprint Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis
    D S Goodin
    Department of Neurology, University of California, San Francisco, Calif 94143 0114, USA
    Neuroepidemiology 18:53-63. 1999
  4. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response
    Douglas S Goodin
    Department of Neurology Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    J Neurol 251:v50-v56. 2004
  5. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors
    Douglas S Goodin
    Department of Neurology, Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, California 94143 0114, USA
    J Neurol 251:v3-v11. 2004
  6. ncbi request reprint Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA 94121, USA Email
    Curr Med Res Opin 23:2823-32. 2007
  7. ncbi request reprint Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response
    D S Goodin
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Drugs 61:1693-703. 2001
  8. ncbi request reprint Therapeutic developments in multiple sclerosis
    D S Goodin
    Department of Neurology, M 794, University of California, San Francisco, CA 94143 0114, USA
    Expert Opin Investig Drugs 9:655-70. 2000
  9. ncbi request reprint Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0114, USA
    Ann Neurol 59:597-605. 2006
  10. doi request reprint Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
    Douglas S Goodin
    University of California, San Francisco, San Francisco, CA 94143 0114, USA
    J Neurol Neurosurg Psychiatry 83:282-7. 2012

Collaborators

Detail Information

Publications30

  1. ncbi request reprint Marijuana and multiple sclerosis
    Douglas Goodin
    Department of Neurology, University of California San Francisco, USA
    Lancet Neurol 3:79-80. 2004
  2. ncbi request reprint Treatment of multiple sclerosis with human beta interferon
    D S Goodin
    Department of Neurology, University of California at San Francisco, Fort Miley Veterans Administration Hospital, 94121, USA
    Int MS J 12:96-108. 2005
    ..Future therapeutic developments in MS will be fuelled by our increasing understanding of the physical and biological roles of the interferons, in health and in MS pathogenesis...
  3. ncbi request reprint Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis
    D S Goodin
    Department of Neurology, University of California, San Francisco, Calif 94143 0114, USA
    Neuroepidemiology 18:53-63. 1999
    ..This review considers several recently published therapeutic trials in order to exemplify some of the difficulties that commonly arise in this area of clinical research...
  4. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response
    Douglas S Goodin
    Department of Neurology Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143 0114, USA
    J Neurol 251:v50-v56. 2004
    ..It is the purpose of this manuscript, therefore, to provide an overview of this process using examples from two recently completed assessments on disease-modifying therapies in multiple sclerosis...
  5. ncbi request reprint Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors
    Douglas S Goodin
    Department of Neurology, Room M794, University of California San Francisco, 505 Parnassus Avenue, San Francisco, California 94143 0114, USA
    J Neurol 251:v3-v11. 2004
    ....
  6. ncbi request reprint Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA 94121, USA Email
    Curr Med Res Opin 23:2823-32. 2007
    ....
  7. ncbi request reprint Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response
    D S Goodin
    Department of Neurology, University of California, San Francisco 94143 0114, USA
    Drugs 61:1693-703. 2001
    ..As a result, it is possible that the apparent dose-response observed in these clinical trials may be due, in part, to the more frequent dose administration schedule rather than the total weekly dose...
  8. ncbi request reprint Therapeutic developments in multiple sclerosis
    D S Goodin
    Department of Neurology, M 794, University of California, San Francisco, CA 94143 0114, USA
    Expert Opin Investig Drugs 9:655-70. 2000
    ..Moreover, it also seems likely that, increasingly, therapeutic strategies that enhance or promote myelin repair will become a major focus of clinical research in this area...
  9. ncbi request reprint Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment?
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, San Francisco, CA 94143 0114, USA
    Ann Neurol 59:597-605. 2006
    ....
  10. doi request reprint Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis
    Douglas S Goodin
    University of California, San Francisco, San Francisco, CA 94143 0114, USA
    J Neurol Neurosurg Psychiatry 83:282-7. 2012
    ..Although randomised controlled trials (RCTs) demonstrate therapeutic benefits on short term outcomes, the relationship between these outcomes and late disability is not established...
  11. pmc The genetic and environmental bases of complex human-disease: extending the utility of twin-studies
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e47875. 2012
    ..Also, susceptible men (compared to susceptible women) have a lower threshold, a greater hazard-rate, or both in response to the environmental factors involved in MS pathogenesis...
  12. pmc Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes
    Jeffrey M Gelfand
    University of California, San Francisco Department of Neurology, Multiple Sclerosis Center, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 7:e36847. 2012
    ....
  13. doi request reprint Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS
    A T Reder
    Department of Neurology, University of Chicago, Chicago, IL 60637, USA
    Neurology 74:1877-85. 2010
    ..The 16-Year Long-Term Follow-Up (LTF) to the pivotal interferon-beta-1b (IFNbeta-1b) trial explored clinical, MRI, cognitive, and patient-reported outcomes. Here, we report the safety assessments...
  14. pmc Switching multiple sclerosis patients with breakthrough disease to second-line therapy
    Tamara Castillo-Trivino
    Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 6:e16664. 2011
    ..The effect of natalizumab monotherapy in patients with breakthrough disease is unknown...
  15. pmc The causal cascade to multiple sclerosis: a model for MS pathogenesis
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, USA
    PLoS ONE 4:e4565. 2009
    ..The first acts near birth, the second acts during childhood, and the third acts long thereafter. Two candidate factors (vitamin D deficiency and Epstein-Barr viral infection) seem well suited to the first two environmental events...
  16. doi request reprint Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial
    Douglas S Goodin
    University of California at San Francisco, CA 94143 0114, USA
    Mult Scler 18:181-95. 2012
    ..The frequency and impact of neutralizing antibodies (NAbs) to interferon beta-1b (IFNβ-1b) on clinical and radiographic outcomes is controversial...
  17. pmc Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS
    Douglas S Goodin
    Department of Neurology, University of California San Francisco, San Francisco, California, United States of America
    PLoS ONE 6:e22444. 2011
    ..For example, although disease-modifying therapy in MS has a convincing benefit on several short-term outcome-measures in randomized trials, its impact on long-term function remains uncertain...
  18. pmc Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci
    Nikolaos A Patsopoulos
    Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Ann Neurol 70:897-912. 2011
    ..To perform a 1-stage meta-analysis of genome-wide association studies (GWAS) of multiple sclerosis (MS) susceptibility and to explore functional consequences of new susceptibility loci...
  19. doi request reprint Disease-modifying therapy in multiple sclerosis: update and clinical implications
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    Neurology 71:S8-13. 2008
    ..Second, high-dose IFN beta-1a or IFN beta-1b subcutaneous has a similar clinical impact to glatiramer acetate, although IFN beta subcutaneous is superior on some MRI outcome measures...
  20. doi request reprint Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution
    Jacqueline F Marcus
    Department of Neurology, University of California, San Francisco, 350 Parnassus Ave, 908, PO Box 0114, San Francisco, CA 94143, USA
    Arch Neurol 69:129-32. 2012
    ..To describe a patient with multiple sclerosis (MS) who developed severe hypercalcemia, attributed to the additive effect of 5500 IU of cholecalciferol and 2020 mg of calcium daily...
  21. pmc The genetic basis of multiple sclerosis: a model for MS susceptibility
    Douglas S Goodin
    Department of Neurology, University of California, San Francisco, CA, USA
    BMC Neurol 10:101. 2010
    ..MS-pathogenesis is known to involve both multiple environmental events, and several independent genetic risk-factors...
  22. doi request reprint Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis
    Bruce A C Cree
    Multiple Sclerosis Center at University of California, San Francisco, 94117, USA
    Ann Neurol 68:145-50. 2010
    ..To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients...
  23. doi request reprint Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis
    Sergio E Baranzini
    Department of Neurology, University of California, San Francisco, CA 94143 0435, USA
    Hum Mol Genet 18:767-78. 2009
    ..Gene ontology-based analysis shows a functional dichotomy between genes involved in the susceptibility pathway and those affecting the clinical phenotype...
  24. ncbi request reprint Neuromyelitis optica
    Bruce A C Cree
    Department of Neurology, University of California San Francisco, USA
    Semin Neurol 22:105-22. 2002
    ..The history of NMO, its nosology, associations with other diseases, and current concepts of its pathogenesis and treatment is reviewed in this article...
  25. ncbi request reprint Interferons in relapsing remitting multiple sclerosis
    Douglas S Goodin
    Lancet 361:1821; author reply 1823-4. 2003
  26. ncbi request reprint A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis
    Douglas S Goodin
    Neurology 67:1313-4. 2006
  27. ncbi request reprint IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event
    Douglas S Goodin
    Neurology 67:1104; author reply 1104-5. 2006
  28. ncbi request reprint Overdiagnosis of multiple sclerosis by magnetic resonance imaging
    Douglas S Goodin
    Ann Neurol 59:575-6; author reply 576. 2006
  29. ncbi request reprint Relationship between multiple sclerosis exacerbations and stress
    Douglas S Goodin
    Psychosom Med 66:287-9; author reply 287-9. 2004
  30. doi request reprint The impact of war-stress on MS exacerbations
    Douglas S Goodin
    Ann Neurol 64:114-5. 2008